Literature DB >> 6678869

Pharmacokinetic study of methyl glyoxal-bis-guanylhydrazone (methyl-GAG).

M Slavik, T Clouse, A Wood, O Blanc, R C Eschbach.   

Abstract

Using a paired ion exchange high pressure liquid chromatographic assay, pharmacokinetic evaluation of methyl glyoxal bis guanylhydrazone (methyl-GAG) was performed in nine male New Zealand albino rabbits following administration of a single intravenous bolus dose of 50 mg/kg B.W (550 mg/m2 BSA). Blood samples were collected before and at intervals of 5, 10, 15, 30 min and 1, 2, 3, 4, 6, 8, 12, 18, and 24 h after administration of the drug. The analysis of experimental data indicates a three compartment open model with first order elimination from the central compartment described by the equation Cpt = A.e-alpha t + B.e-beta t + C.e-gamma t, where A, B, C, are 107.985, 4.785, and 0.763 micrograms/ml, respectively. alpha, beta, gamma, are 5.466, 0.487, and 0.030 h-1, respectively, and T1/2 alpha, beta, gamma are 7.6, 85.3 min and 23.1 h, respectively. The mean volume of distribution in the central compartment Vc was 0.44 liters (1)/kg, volume of distribution Vdarea 30.326 1/kg, and the total body clearance 0.9097 1/kg/h. The existence of a long terminal plasma half life of methyl-GAG reported previously in human studies was also confirmed in experimental animals and may explain the cumulative toxicity of this drug.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6678869     DOI: 10.1007/bf00208893

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  13 in total

Review 1.  Chromomycin A3, mithramycin, and olivomycin: antitumor antibiotics of related structure.

Authors:  M Slavik; S K Carter
Journal:  Adv Pharmacol Chemother       Date:  1975

2.  THE DISTRIBUTION, EXCRETION, AND METABOLISM OF METHYLGLYOXAL-BIS-GUANYLHYDRAZONE-C14.

Authors:  V T OLIVERIO; R H ADAMSON; E S HENDERSON; J D DAVIDSON
Journal:  J Pharmacol Exp Ther       Date:  1963-08       Impact factor: 4.030

3.  TREATMENT OF ACUTE LEUKEMIA WITH METHYLGLYOXAL-BIS-GUANYLHYDRAZONE (METHYL GAG).

Authors:  R H LEVIN; E HENDERSON; M KARON; E J FREIREICH
Journal:  Clin Pharmacol Ther       Date:  1965 Jan-Feb       Impact factor: 6.875

4.  Methylglyoxal bis (guanylhydrazone): a new agent active against acute myelocytic leukemia.

Authors:  E J FREIREICH; E FREI; M KARON
Journal:  Cancer Chemother Rep       Date:  1962-02

5.  Initial clinical study of parenteral methylglyoxal bis(guanylhydrazone) diacetate.

Authors:  W REGELSON; J F HOLLAND
Journal:  Cancer Chemother Rep       Date:  1961-04

6.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

7.  Adriamycin and daunorubicin disposition in the rabbit.

Authors:  N R Bachur; R C Hildebrand; R S Jaenke
Journal:  J Pharmacol Exp Ther       Date:  1974-11       Impact factor: 4.030

8.  High-performance liquid chromatographic assay for methylglyoxal bis(guanylhydrazone) (methyl GAG) in plasma and urine.

Authors:  K C Marsh; A J Repta; L A Sternson
Journal:  J Chromatogr       Date:  1980-01-04

9.  Phase I-II trial of methyl-GAG: a Southwest Oncology Group Pilot Study.

Authors:  W A Knight; R B Livingston; C Fabian; J Costanzi
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

10.  Parenteral formulation of hexamethylmelamine potentially suitable for use in man.

Authors:  M M Ames; J S Kovach
Journal:  Cancer Treat Rep       Date:  1982-07
View more
  1 in total

1.  Alagebrium attenuates acute methylglyoxal-induced glucose intolerance in Sprague-Dawley rats.

Authors:  Arti Dhar; Kaushik M Desai; Lingyun Wu
Journal:  Br J Pharmacol       Date:  2009-12-04       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.